Search

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Wednesday, November 18, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Craig Thompson Awarded Columbia Business School’s Deming Cup for Operational Excellence Craig B. Thompson, MD Craig B. Thompson, MD , President and CEO at MSK, was awarded Columbia

Researchers identify a compound that appears to eliminate tumor cells in a dish and in mice.

… Wednesday, June 19, 2019 Summary MSK researchers identified a new strategy for inhibiting RNA-binding proteins, which play a role in many cancers. Since 2012, Memorial Sloan Kettering cancer biologist Michael Kharas has focused on studying a family of proteins called Musashi. These proteins play a role

The findings will lead to more accurate diagnoses and, potentially, to better treatments.

… Friday, July 20, 2018 Summary Experts say the findings about this type of tumor will lead to more accurate diagnoses and, potentially, to better treatments. In recent years, there have been many advances in treating children with cancer, but brain tumors remain a major challenge. For many pediatric brain

Learn about how nutrition experts are helping people with cancer maintain a healthy diet both during and after treatment.

… Wednesday, March 28, 2018 Summary MSK researchers have shown the crucial role that a healthy diet plays in cancer recovery. They are now developing unique ways to help people who are having transplants maintain good nutrition. People who have stem cell and bone marrow transplants face many challenges

An international team of researchers led by Howard Scher, MD, Co-Chair of the Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center (MSK), has validated a biomarker that can predict whether people with metastatic castration-resistant prostate cancer (mCRPC) may live longer if they are treated with a taxane-based chemotherapy instead of a second targeted androgen receptor–signaling inhibitor (ARSi).

… Thursday, June 28, 2018 Bottom Line: An international team of researchers led by Howard Scher, MD , Co-Chair of the Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center (MSK), has validated a biomarker that can predict whether people

Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive leadership team since 2011, most recently serving as Executive Vice President and Chief Operating Officer.

… Monday, June 26, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive

The event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.

… Friday, March 19, 2021 On March 17, 2021, scientists from around the world tuned in to watch the 2nd Annual Kravis WISE Symposium , a series of scientific talks sponsored by the Marie-Josée Kravis Women in Science Endeavor (WISE) at Memorial Sloan Kettering. Launched in 2020, Kravis WISE is devoted to

The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions -- Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University -- has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.

… Monday, July 31, 2006 First Research Projects to be Funded under the Tri-Institutional Stem Cell Initiative The Tri-Institutional Stem Cell Initiative , comprised of three leading New York City biomedical research institutions — Memorial Sloan Kettering Cancer Center, The Rockefeller University, and

A collaborative team from MSK has uncovered important new findings that explain why ovarian cancer does not respond to immunotherapy.

… Wednesday, December 14, 2022 A team at Memorial Sloan Kettering Cancer Center (MSK) has uncovered several mechanisms of immune escape that can help explain why ovarian cancers have been resistant to immunotherapy to date. The researchers found that ovarian cancer is even more complex than previously

Chemotherapy is a common treatment for acute myeloid leukemia, but patients often stop responding. Until now, not much was known about why.

… Friday, December 2, 2016 Summary Acute myeloid leukemia is usually treated with chemotherapy , but patients often stop responding to these drugs and develop resistance to them. Now MSK investigators are learning why that is the case. Highlights Acute myeloid leukemia is the most common acute leukemia